BIOSCRIP PBM SERVICES/JAI MEDICAL SYSTEMS MANAGED CARE ORGANIZATION, INC.

Call Clinical Services Department at 1-800-555-8513 or Fax 1-800-583-6010. BioScrip will respond by fax or phone within 24 hours of receipt of this request

HEPATITIS C THERAPY PRIOR-AUTHORIZATION FORM

Incomplete form will be returned

<u>Please attach copies of the patient medical history summary, lab and genetic test reports to BioScrip.</u> **Please review our clinical criteria before submitting this form**

Patient Information Recipient: ______ MA#: _____ Date of Birth: _____ /____ Body Weight: _____ kg) -□ Hospital □ Clinic Patient location: □ Home **Diagnosis (Attach genotype test results)** □ Acute Hep C □ Chronic Hep C □ Genotype of pre-transplant liver: _____ ☐ Hepatocellular Carcinoma ☐ Genotype of post-transplant liver: other: What is patient's HCV genotype (including subtype)?_____ Has a liver biopsy been performed? □ Yes □ No Test date : ____/_____ Provide a copy of biopsy results or other fibrosis test, specify Metavir grade: ______ stage: ______ **Hepatitis C Patient Characteristics** This request is for: □ New Therapy □ Relapser □ Partial Responder □ Non-Responder □ Compensated cirrhosis (treatment naïve or experienced) □ No cirrhosis □ Decompensated liver d/s Drug Regimen with Strengths/Dosages/Length of Therapy and Treatment Plan Sovaldi®:_____OlysioTM:_____ Pegylated interferon: Ribavirin: Anticipated total treatment duration: (Adherence with prescribed therapy is a condition for payment for continuation therapy for up to the allowed timeframe for each HCV genotype. The recipient's Medicaid drug history will be reviewed prior to approval.) Has drug therapy treatment plan been developed and discussed with patient \Box Yes \Box No Any issues with drug adherence? □ Yes Explain: □ No Adherence assessment:

Laboratory Results

Dubblatol j Results	
Has a test been performed for the Q80K polymorphism? □ Yes □ No Test date:/	
Baseline HCV RNA level (within 30 day pre-treatment):	log10 Date://
HCV RNA Level at Treatment week 4:lo	og10Date measured:/
at Treatment week 12:lo	og10 Date measured:/
at Treatment week 24 :lo	g10 Date measured:/
Date of HCV RNA rebound (≥ 1 log10 increase from the nadir HCV RNA) any time while on treatment:/	
Liver enzyme levels: Baseline ALT/AST:	Date measured:/
Baseline platelet:	Date measured:/
Baseline hemoglobin/hematocrit:	Date measured://
Medical History	
Does patient have HIV/HCV co-infection? □Yes □ No	
Has patient had a solid organ transplant? □ Yes □ No Specify transplant date:/	
Does the patient have a history of any of the following: □ anemia □ autoimmune hepatitis or other autoimmune conditions □ severe concurrent medical d/s (i.e. AIDS, cancer, significant CAD) □ currently on didanosine □ unstable CVD	
Does patient have history of depression or mood disorder? □ Yes □ No If yes, is patient stable on current medication? □Yes □ No	
Does patient have history of Drug/Alcohol Abuse? □Yes □ No If yes, is patient abstinent for last 6 months? □Yes □ No If no, is patient currently in drug rehabilitation program? □ Yes □No	
Prior Drug Utilization	
List concomitant drugs that might interact with any of the prescribed Hep C drugs:	
List all previous hepatitis C therapies including adverse effects associated with prior therapy and reason for drug failure. If the patient is contraindicated or ineligible to receive a portion of a therapy (interferon), please provide a reason:	
If patient's Medicaid eligibility change during therapy and patient is no longer eligible for Medicaid prescription drug assistance, is the physician prepared to enroll the patient in other patient assistant drug programs to complete therapy? □ YES □ NO	
I certify that the information provided is accurate. Supporting documentation is available for audits.	
Drasorihar's Now	ne: Date:/
(Prescriber's signature)	Date//
Practice Specialty:	
Telephone# () –	Fax# (
Address:	

(DHMH 0514) Page **2** of **2**